We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

406 hedge funds and large institutions have $2.5B invested in CRISPR Therapeutics in 2023 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 155 increasing their positions, 101 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 155 | Existing positions reduced: 101

0.32% less ownership

Funds ownership: 69.41% → 69.09% (-0.32%)

3% less funds holding

Funds holding: 418 → 406 (-12)

12% less call options, than puts

Call options by funds: $80.5M | Put options by funds: $91.5M

15% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 53

19% less capital invested

Capital invested by funds: $3.07B → $2.5B (-$575M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
406
Holders Change
-12
Holders Change %
-2.87%
% of All Funds
6.44%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
45
Increased
155
Reduced
101
Closed
53
Calls
$80.5M
Puts
$91.5M
Net Calls
-$11M
Net Calls Change
-$41M

Top Buyers

Rank Fund Capital Flow
1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$15.4M
2
State Street
State Street
Massachusetts
+$13M
3
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$10.2M
4
IHAM
Integral Health Asset Management
New York
+$9.04M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$8.7M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$16.6M
2
VCM
Valiant Capital Management
California
-$12.9M
3
Two Sigma Investments
Two Sigma Investments
New York
-$11M
4
AIM
ARK Investment Management
Florida
-$9.06M
5
Renaissance Technologies
Renaissance Technologies
New York
-$7.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
ADL
376
Asset Dedication LLC
California
$2K – – –
RWPA
377
Richard W. Paul & Associates
Michigan
$1.91K – – –
MWM
378
Mascoma Wealth Management
New Hampshire
$1.86K – – –
BIA
379
Bell Investment Advisors
California
$1.54K +$1.76K +34 New
ME
380
McIlrath & Eck
Washington
$1.41K – – –
PP
381
Pacifica Partners
Canada
$1.29K – – –
CT
382
Colonial Trust
South Carolina
$1.14K – – –
GI
383
Gradient Investments
Minnesota
$1.14K – – –
KA
384
Kozak & Associates
Colorado
$1.12K – – –
IFAM
385
Institutional & Family Asset Management
Colorado
$953 – – –
AIC
386
Archer Investment Corporation
Indiana
$908 – – –
TFM
387
TFC Financial Management
Massachusetts
$908 – – –
AWA
388
Authentikos Wealth Advisory
California
$817 +$930 +18 New
CAS
389
Coppell Advisory Solutions
Texas
$813 – – –
JWM
390
Janiczek Wealth Management
Colorado
$772 – – –
OP
391
ORG Partners
Indiana
$680 +$775 +15 New
Kayne Anderson Rudnick Investment Management
392
Kayne Anderson Rudnick Investment Management
California
$635 – – –
TC
393
Truvestments Capital
Florida
$635 – – –
NSIM
394
North Star Investment Management
Illinois
$590 – – –
QT
395
Quantbot Technologies
New York
$590 +$671 +13 New
KFI
396
Key Financial Inc
Pennsylvania
$545 – – –
DSC
397
Duncker Streett & Co
Missouri
$499 – – –
CFFP
398
Center for Financial Planning
Michigan
$454 – – –
CFB
399
Cullen/Frost Bankers
Texas
$454 – – –
NSG
400
Nalls Sherbakoff Group
Tennessee
$318 – – –
14 15
16
17 18

CRSP Hedge Fund Activity: Q3 2023 in Review

406 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2023, worth a combined $2.5B — down 19% from $3.07B a quarter earlier.

Sellers outnumbered buyers: 53 funds closed out of CRSP and 45 opened new positions — a net loss of 8 holders — while 101 trimmed existing stakes and 155 added.

The largest buyer was Westfield Capital Management, opening a new position worth an estimated $15.4M. The largest seller was Marshall Wace, cutting an estimated $16.6M.

  • 406 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2023, down from 418 in Q2 2023.
  • Funds reported $2.5B of CRISPR Therapeutics stock for Q3 2023, down 19% quarter-over-quarter.
  • 45 funds opened new CRISPR Therapeutics positions in Q3 2023 and 53 closed out, a net change of -8 holders.
  • The largest CRISPR Therapeutics buyer in Q3 2023 was Westfield Capital Management, an estimated $15.4M added.
  • The largest CRISPR Therapeutics seller in Q3 2023 was Marshall Wace, an estimated $16.6M sold.

Based on aggregated 13F filings for Q3 2023.